Introduction
Executive Summary
MTORC1 protein inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
MTORC1 protein inhibitors - DelveInsight's Analytical Perspective
In-depth Commercial Assessment
• MTORC1 protein inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends
MTORC1 protein inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Pre-registration)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Onatasertib (CC 223): Celgene
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
CERC 006: Cerecor
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Research programme: mTOR inhibitors: Mount Tam Biotechnologies
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
MTORC1 protein inhibitors Key Companies
MTORC1 protein inhibitors Key Products
MTORC1 protein inhibitors- Unmet Needs
MTORC1 protein inhibitors- Market Drivers and Barriers
MTORC1 protein inhibitors- Future Perspectives and Conclusion
MTORC1 protein inhibitors Analyst Views
MTORC1 protein inhibitors Key Companies
Appendix

List of Tables
Table 1 Total Products for MTORC1 protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for MTORC1 protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Key Companies
• Celgene
• Takeda Oncology
• Mount Tam Biotechnologies
• Cerecor
• Adicet Bio
• Aeonian Pharmaceuticals
• Boehringer Ingelheim
• REVOLUTION Medicines